CN Patent

CN118510503A — 多西他赛组合物和方法

Assigned to Zhuhai Beihai Biotech Co Ltd · Expires 2024-08-16 · 2y expired

What this patent protects

本申请提供了含有多西他赛和人血清白蛋白的药物组合物。该组合物具有不包含任何聚山梨酯80表面活性剂的优势，并且可以用于以75mg/m 2 的剂量向患者输注多西他赛。该组合物可用于治疗癌症，例如乳腺癌、非小细胞肺癌、前列腺癌、胃癌或头颈癌。

USPTO Abstract

本申请提供了含有多西他赛和人血清白蛋白的药物组合物。该组合物具有不包含任何聚山梨酯80表面活性剂的优势，并且可以用于以75mg/m 2 的剂量向患者输注多西他赛。该组合物可用于治疗癌症，例如乳腺癌、非小细胞肺癌、前列腺癌、胃癌或头颈癌。

Drugs covered by this patent

Patent Metadata

Patent number
CN118510503A
Jurisdiction
CN
Classification
—
Expires
2024-08-16
Drug substance claim
No
Drug product claim
No
Assignee
Zhuhai Beihai Biotech Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.